Founded with a mission to revolutionize biopharmaceutical development, GenNext Technologies specializes in Hydroxyl Radical Protein Footprinting (HRPF) to advance the study of protein conformations and accelerate the development of biopharmaceuticals and biosimilars. Their core offerings include the AutoFox and Fox systems, which provide cutting-edge solutions for protein footprinting and structural biology research. The company targets the biopharmaceutical sector, focusing on monoclonal antibody (mAb) services and other protein-based therapeutics.

GenNext Technologies boasts a distinguished team, including an executive team, a scientific advisory board, and a board of directors with extensive experience in biotechnology and pharmaceuticals. The company has garnered support from notable partners and distributors, as well as funding from the National Institutes of Health (NIH). Key achievements include the development of proprietary HRPF technology that has significantly impacted protein research methodologies. Overall, GenNext Technologies has made substantial contributions to the field of structural biology and biopharmaceutical innovation.